目的：探讨米氮平与帕罗西汀治疗抑郁症的疗效和安全性。方法将78例抑郁症患者随机分为两组，分别口服米氮平和帕罗西汀治疗，观察8周。治疗前后采用汉密顿抑郁量表评定临床疗效，副反应量表评定不良反应。结果治疗后两组汉密顿抑郁量表评分均较治疗前显著下降（P＜0．01），米氮平组治疗第1周末较帕罗西汀组下降更显著（P＜0．01），治疗8周末米氮平组显效率为74．4％、总有效率为92．3％，帕罗西汀组分别为71．8％、94．9％，两组比较差异无显著性（χ2＝0．07、0．21，P＞0．05）。治疗后两组不良反应均轻微，发生率比较差异无显著性（P＞0．05）。结论米氮平与帕罗西汀治疗抑郁症疗效显著，总体疗效相当，但米氮平较帕罗西汀起效更快，更有利于增加患者早期的治疗信心，提高患者的生活质量。、Objective To explore the efficacy and safety of mirtazapine and paroxetine in the treatment of depression .Methods Seventy‐eight depression patients were randomly assigned to two groups taking o‐rally mirtazapine or paroxetine for 8 weeks .Efficacies were assessed with the Hamilton Depression Scale (HAMD) before and after treatment and adverse reactions with the Treatment Emergent Symptom Scale (TESS) .Results After treatment the HAMD scores of both groups lowered more significantly compared with pretreatment (P< 0 .01) ,so did that in mirtazapine than in paroxetine group at the end of the 1st week (P<0 .01) ,at the end of the 8th week obvious and total effective rate were respectively 74 .4% and 92 .3% in mirtazapine and 71 .8% and 94 .9% in paroxetine group ,which showed no significant group differences (χ2 =0 .07 ,0 .21;P>0 .05) .Adverse reactions of both groups were mild and their incidences had no significant group differences (P>0 .05) .Conclusion Both mirtazapine and paroxetine have an evi‐dent effect in depression ,their total efficacies are equivalent ,but the former takes effect more rapidly and is beneficial to the increase of early treatment confidence and the improvement of patients ’ quality of life .